MA29680B1 - VACCINE - Google Patents
VACCINEInfo
- Publication number
- MA29680B1 MA29680B1 MA30332A MA30332A MA29680B1 MA 29680 B1 MA29680 B1 MA 29680B1 MA 30332 A MA30332 A MA 30332A MA 30332 A MA30332 A MA 30332A MA 29680 B1 MA29680 B1 MA 29680B1
- Authority
- MA
- Morocco
- Prior art keywords
- vaccine
- protocol
- kit according
- adjuvant
- mpl
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
24. Utilisation, procédé, protocole, vaccin ou trousse selon l'une quelconque des revendications précédentes, où la protéine L1 de HPV est sous la forme d'une particule analogue à un virus. 25. Utilisation, procédé, protocole, vaccin ou trousse selon l'une quelconque des revendications précédentes, où le premier ou le deuxième vaccin ou les deux comprennent un adjuvant. 26. Utilisation, procédé, protocole, vaccin ou trousse selon la revendication 25, où l'adjuvant comprend du 3D-MPL. 27. Utilisation, procédé, protocole, vaccin ou trousse selon la revendication 25, où l'adjuvant comprend un sel d'aluminium. 28. Utilisation, procédé, protocole, vaccin ou trousse selon la revendication 26 ou 27, où l'adjuvant comprend un sel d'aluminium et du 3D MPL. 29. Utilisation, procédé, protocole, vaccin ou trousse selon la revendication 26, où l'adjuvant comprend un adjuvant en émulsion huile dans l'eau et du 3D-MPL. 30. Utilisation, procédé, protocole, vaccin ou trousse selon la revendication 29, où l'émulsion huile dans l'eau comprend une huile métabolisable, un stérol et un agent émulsionnant.Use, process, protocol, vaccine or kit according to any one of the preceding claims, wherein the HPV L1 protein is in the form of a virus-like particle. Use, process, protocol, vaccine or kit according to any one of the preceding claims, wherein the first or second vaccine or both comprise an adjuvant. Use, process, protocol, vaccine or kit according to claim 25, wherein the adjuvant comprises 3D-MPL. Use, process, protocol, vaccine or kit according to claim 25, wherein the adjuvant comprises an aluminum salt. Use, process, protocol, vaccine or kit according to claim 26 or 27, wherein the adjuvant comprises an aluminum salt and 3D MPL. Use, process, protocol, vaccine or kit according to claim 26, wherein the adjuvant comprises an oil-in-water emulsion adjuvant and 3D-MPL. Use, process, protocol, vaccine or kit according to claim 29, wherein the oil-in-water emulsion comprises a metabolizable oil, a sterol and an emulsifying agent.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67482905P | 2005-04-26 | 2005-04-26 | |
GB0509010A GB0509010D0 (en) | 2005-05-03 | 2005-05-03 | Vaccine |
PCT/EP2005/006461 WO2005123125A1 (en) | 2004-06-16 | 2005-06-14 | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29680B1 true MA29680B1 (en) | 2008-08-01 |
Family
ID=42334364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30332A MA29680B1 (en) | 2005-04-26 | 2007-10-29 | VACCINE |
Country Status (2)
Country | Link |
---|---|
IL (1) | IL186586A0 (en) |
MA (1) | MA29680B1 (en) |
-
2007
- 2007-10-11 IL IL186586A patent/IL186586A0/en unknown
- 2007-10-29 MA MA30332A patent/MA29680B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL186586A0 (en) | 2008-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wieland et al. | Erythroplasia of queyrat: coinfection with cutaneous carcinogenic human papillomavirus type 8 and genital papillomaviruses in a carcinoma in situ | |
AP1872A (en) | Virus-like particles of human papillomavirus. | |
CA2443214A1 (en) | Vaccine composition comprising human papilloma virus 16 l1 virus-like particle (hpv 16 l1 vlp), human papilloma virus 18 l1 virus-like particle (hpv 18 l1 vlp) and 3-de-o-acylatedmonphosphoryl lipid a (3d-mpl) and alum | |
BRPI0810959A2 (en) | "hpv11 l1 protein, polynucleotide, vector, cell, composition, virus-like particle (vlp) hp11, method for producing an hpv l1 protein, vaccine for prevention of acuminate condyloma or hpv infections, use of the protein prevention method of acuminate condyloma or hpv infections and method for prevention of acuminate condyloma or hpv infections. | |
JP2011225578A5 (en) | ||
HK1085378A1 (en) | Use of hpv16 and hpv18 as vaccine against one or more of oncogenic hpv type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 | |
EA200700338A1 (en) | INHIBITORS OF RNA-DEPENDENT RNA POLYMERASE OF THE VIRUS HEPATITIS C AND COMPOSITIONS AND METHODS OF TREATMENT USING THEM | |
AU7812800A (en) | Diagnosis method of fibrotic disease using biochemical markers | |
EP2340830A3 (en) | Hepatitis C Virus Inhibitors | |
JP2003526673A5 (en) | ||
EP2377551A3 (en) | Adjuvanted influenza vaccines including cytokine-inducing agents | |
JP2006512413A5 (en) | ||
SG160328A1 (en) | Adjuvant composition comprising aluminium phosphate and 3d-mpl | |
MA29680B1 (en) | VACCINE | |
SG153837A1 (en) | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 | |
ATE380034T1 (en) | NEW METHOD FOR PRODUCING VIRUS-LIKE PARTICLES OF THE HUMAN PAPILLOMA VIRUS WITH IMPROVED PROPERTIES | |
TW200612983A (en) | Vaccine | |
RU2016141621A (en) | WAYS OF STRENGTHENING EFFECTIVENESS OF IMMUNITY OF VACCINES ADSORPED ON SALTS OF ALUMINUM | |
GB2555748A (en) | Novel form of isoxadifen-ethyl, process for preparation and use thereof | |
EA200702077A1 (en) | VACCINE | |
SI1572233T1 (en) | Use of HPV16 and HPV18 as vaccine against one or more of oncogenic HPV type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 | |
Li-ming | Sporo-pollen assemblages from late phase of Early Cretaceous in Minhe Basin | |
NZ567982A (en) | Influenza vaccines extemporaneously adsorbed to aluminium adjuvants | |
RU2452729C2 (en) | Biphenyl derivatives and application thereof in treating hepatitis c | |
MA29679B1 (en) | VACCINE |